«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年04期

页码:

353-356

栏目:

技术与方法

出版日期:

2018-07-20

文章信息/Info

Title:

H3K27me3 is a highly sensitive diagnostic marker for MPNST

作者:

宋紫暄¹; 李光明¹; 张 静¹; 张卫民²; 杨吉龙³;  朱 泽¹

1.天津医科大学病原生物学系, 天津300070；2.天津市第三中心医院输血科，天津 300170；3.天津医科大学肿瘤医院骨与软组织肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060

Author(s):

SONG Zi-xuan¹;  LI Guang-ming¹;  ZHANG Jing¹;  ZHANG Wei-min²;  YANG Ji-long²;  ZHU Ze¹

1. Department of Pathogen Biology，Tianjin Medical University，Tianjin 300070，China；2. Department of Blood Transfusion, The Third Central Hospital of Tianjin, Tianjin 300170, China；3. Department of Bone and Soft Tissue Tumor, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin 300060, China

关键词:

恶性周围神经鞘瘤; H3K27me3; NF1; 组织芯片

Keywords:

malignant peripheral nerve sheath tumor;  H3K27me3;  NF1;  tissue microarray

分类号:

R73

DOI:

-

文献标志码:

Ａ

摘要:

目的：探讨组蛋白3赖氨酸27位点的三甲基化（H3K27me3）在恶性周围神经鞘瘤（MPNST) 中的表达及对预后的影响。方法：收集恶性周围神经鞘瘤病理组织标本43例，经福尔马林固定，石蜡包埋后，利用组织芯片技术（TMA）制成组织芯片，免疫组织化学方法检测 H3K27me3 等蛋白的表达，根据临床数据和随访信息，运用SPSS 19.0统计软件进行分析比较不同H3K27me3表达水平与患者临床病理特征之间的关系。结果：MPNST组织芯片位点完整。H3K27me3表达缺失组约占 65.11% ，其中完全缺失组占39.53％，部分缺失组约占25.58%，即以H3K27me3表达缺失为诊断依据则MPNST的检出率可达65.11%，且与原诊断一致；在39例散发病例样本中有43.58%完全缺失、28.20%部分缺失，4例NF1相关样本100％保留表达，即在非NF1相关的MPNST中检出率可达71.78%。结论：检测H3K27me3的表达水平对MPNST的诊断具有良好的灵敏性和特异性，特别是在除外NF1相关临床背景的MPNST前期诊断中具有重要意义，有望成为早期诊断散发型MPNST的生物学标记物。

Abstract:

Objective: To investigate the expression and prognostic effect of H3K27 trimethylation protein(H3K27me3) in malignant peripheral nerve sheath tumor (MPNST)． Methods: A total of 43 MPNST patients were enrolled into this study． Tissue microarray (TMA) technique and immunohistochemistry (IHC) method were used for H3K27me3 immunostaining. Clinicopathologic and suvival data were carefully collected. The relationship of H3K27me3 expression levels with clinical feature and prognosis of patients were compared by SPSS 19.0． Results: The quality of TMA was perfect and met the standard of analysis. Among all MPNST patients，65.11% were characterized with loss expression of H3K27me3, 39.53% were with complete loss expression and 25.58% were with partial loss expression of H3K27me3. If loss expression of H3K27me3 was a diagnostic basis for MPNST, the detectable rate was 65.11%，in accordance with original diagnosis. Among the 39 sporadic MPNST patients, 43.58% were with complete loss expression of H3K27me3, and the partial loss patients were 28.20%. All of the type 1 neurofibromatosis (NF1) MPNSTs expressed H3K27me3. The detectable rate was 71.78% outside of NF1 clinical history MPNST. Conclusion: Immunohistochemical analysis of H3K27me3 has good sensitivity and specificity for the diagnosis of MPNST, particularly outside NF1 clinical history. Loss of H3K27me3 expression may be a sensitive marker for sporadic MPNST.

参考文献/References:

[1] Toro J R, Travis L B, Wu H J, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases[J].Inter J Cancer, 2006, 119(12):2922
[2] Ducatman B S, Scheithauer B W. Postirradiation neurofibrosarcoma[J]. Cancer, 1983, 51(6):1028
[3] Foley K M, Woodruff J M, Ellis F T, et al. Radiation-induced malignant and atypical peripheral nerve sheath tumors[J]. Ann Neurol, 1980, 7(4):311
[4] Bradford D, Kim A. Current treatment options for malignant peripheral nervesheath tumors[J]. Curr Treat Options Oncol, 2015,16(3):328
[5] Shepard T H, Tucci D L, Grant G A, et al. Management of hearing in pediatricNF2[J].Otol Neurotol, 2012,33(6):1066
[6] Lafemina J, Qin L X, Moraco N H, et al. Oncologic outcomes of sporadic,neurofibromatosis-associated, and radiation-induced malignant peripheral nervesheath tumors[J]. Ann Surg Oncol,2013,20(1):66
[7] Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group[J]. J Pathol, 2000,190(1):31
[8] Matsunou H, Shimoda T, Kakimoto S, et al. Histopathologic and immunohistochemical study of malignant tumors of peripheral nerve sheath (malignant schwannoma) [J]. Cancer, 1985,56(9):2269
[9] Nakajima T, Watanabe S, Sato Y, et al. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues[J]. Am J Surg Pathol, 1982, 6(8):715
[10] Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decit-abineare highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL[J]. Blood,2011, 118(20):5506
[11] YooK H,Hennighausen L.EZH2 methyltransferase and H3K27 methylation in breast cance[J]. Int J Biol Sci, 2012, 8(1):59
[12] Prieto-Granada C N, Wiesner T, Messina J L, et al.Loss of H3K27me3 ExpressionIs a Highly Sensitive Marker for Sporadic and Radiation-inducedMPNST[J]. Am J Surg Pathol, 2016, 40(4):479
[13] Asano N, Yoshida A, Ichikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours[J]. Histopathology, 2017, 70(3):385
[14] Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors[J]. Nat Genet, 2014, 46(11):1227
[15] Zhang M, Wang Y X, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors[J]. Nat Genet, 2014, 46(11):1170
[16] Luscan A, Vidaud D, Ortonne N, et al. PRC2 alterations in NF1-associated malignant peripheral nerve sheath tumors: schwann cells with no complex[J]. Med Sci (Paris), 2014, 30(8/9):733
[17] Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in Life[J]. Nature, 2011,469(7330):343

相似文献/References:

[1]赵洋,孙亚敏,朱香熹,等.LATS2对恶性周围神经鞘瘤细胞的调控作用及分子机制探讨[J].天津医科大学学报,2023,29(02):120.
　ZHAO Yang,SUN Ya-min,ZHU Xiang-xi,et al.Regulatory effect and molecular mechanism of LATS2 on malignant peripheral nerve sheath tumor cells[J].Journal of Tianjin Medical University,2023,29(04):120.
[2]孙亚敏,朱香熹,陈毓锴,等.萝卜硫素预防Ⅰ型神经纤维瘤病恶性进展的作用机制研究[J].天津医科大学学报,2024,30(02):105.[doi:10.20135/j.issn.1006-8147.2024.02.0105]
　SUN Yamin,ZHU Xiangxi,CHEN Yukai,et al.The effect and mechanism of sulforaphane in preventing malignant progression of neurofibromatosis type Ⅰ[J].Journal of Tianjin Medical University,2024,30(04):105.[doi:10.20135/j.issn.1006-8147.2024.02.0105]
[3]孙硕遥,高雅,朱香熹,等.吉非替尼通过促进H3K27甲基化水平抑制恶性周围神经鞘瘤细胞的增殖[J].天津医科大学学报,2021,27(03):211.
　SUN Shuo-yao,GAO Ya,ZHU Xiang-xi,et al.Gefitinib inhibits the proliferation of malignant peripheral nerve sheath tumor cells by promoting H3K27 methylation levels[J].Journal of Tianjin Medical University,2021,27(04):211.
[4]高雅,赵洋,朱香熹,等.司美替尼对恶性周围神经鞘瘤细胞增殖和凋亡的影响[J].天津医科大学学报,2022,28(01):40.
　GAO Ya,ZHAO Yang,ZHU Xiang-xi,et al.The effect of selumetinib on cell proliferation and apoptosis of malignant peripheral nerve sheath tumor[J].Journal of Tianjin Medical University,2022,28(04):40.

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 2018-07-20